Clinical research
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
Adastra Pharmaceuticals’ positive results from a Phase Ib trial of its therapy for recurrent high-grade glioblastomas suggest an effective treatment could be available within the next several years.
The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space.
PRESS RELEASES